Health Insurance Coverage for CAR T-Cell Therapies:
HB 725 would require certain Florida health insurance arrangements that cover CAR T-cell therapy to treat in-network health care facilities as covered providers for the administration of that therapy. The bill applies to individual health insurance policies, group health insurance policies, and health maintenance contracts issued, delivered, or renewed on or after January 1, 2026. If a facility is already in a plan’s network for any other service, the plan could not refuse to contract with that facility for CAR T-cell therapy services, including the administration of CAR T cells, related medications, and any necessary procedures, so long as the therapy follows FDA-approved guidelines and procedures.
The bill defines CAR T cells and CAR T-cell therapy as a cancer treatment using a patient’s own modified T cells infused to attack cancerous cells, sometimes after chemotherapy or radiation. It creates three new statutory sections in Florida law—one each for individual policies, group policies, and health maintenance contracts—so the same coverage rule applies across major private health coverage types. The act would take effect January 1, 2026.
HB 725 would amend Florida insurance law by adding new coverage and network-access requirements for CAR T-cell therapies in chapters governing individual health insurance policies, group health insurance policies, and health maintenance contracts. It would limit insurers’ ability to exclude otherwise in-network facilities from providing CAR T-cell therapy and would prohibit denial of coverage for the therapy when performed by an in-network facility under FDA-approved protocols. The practical effect is to expand access to this specialized cancer treatment and reduce insurer discretion over where covered patients may receive it.
The available record shows no committee transcript or recorded vote on the bill, and the measure ultimately died in the Health Care Facilities & Systems Subcommittee. Based on the bill text, the proposal appears to be framed as a patient-access and cancer-treatment coverage measure rather than a broad insurance overhaul. The lack of recorded debate makes it difficult to identify detailed support or opposition, but the bill’s narrow focus suggests it was likely viewed as a targeted health coverage mandate.
The main potential point of contention is the mandate on insurers and health maintenance organizations to contract with in-network facilities for a highly specialized and potentially costly cancer therapy. Insurers may object to limits on network management, utilization control, and contracting discretion, while supporters would likely emphasize access to advanced cancer treatment and continuity of care at facilities already in network for other services. Another possible issue is the bill’s application only to policies issued, delivered, or renewed on or after January 1, 2026, which may affect how quickly patients would benefit.